Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)

Clinical Trial ID NCT01848834

PubWeight™ 38.24‹?›

🔗 Visit the page for NCT01848834

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015 2.25
2 The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther 2015 1.73
3 Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015 1.67
4 Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016 1.54
5 Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol 2015 1.45
6 Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol 2016 1.26
7 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
8 Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014 1.22
9 Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016 1.22
10 Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016 1.12
11 Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol 2015 1.10
12 Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut 2016 1.06
13 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
14 New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 2015 1.02
15 Emerging molecular classifications and therapeutic implications for gastric cancer. Chin J Cancer 2016 1.00
16 Pembrolizumab. J Immunother Cancer 2015 0.99
17 Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget 2015 0.99
18 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
19 Muscle-invasive urothelial bladder cancer: an update on systemic therapy. Ther Adv Urol 2015 0.98
20 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
21 Advances in the management of gastrointestinal cancers--an upcoming role of immune checkpoint blockade. J Hematol Oncol 2015 0.91
22 Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol 2015 0.89
23 Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol 2017 0.85
24 Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel) 2014 0.85
25 Immune checkpoints: A therapeutic target in triple negative breast cancer. Oncoimmunology 2014 0.85
26 Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer 2016 0.83
27 The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. J Gastrointest Oncol 2016 0.83
28 Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int 2015 0.82
29 The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist 2015 0.81
30 Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res 2016 0.81
31 Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol 2015 0.81
32 The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016 0.78
33 New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. Clin Cancer Res 2015 0.78
34 Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer. Therap Adv Gastroenterol 2016 0.78
35 Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing. Breast Cancer Res Treat 2013 0.77
36 Immunological battlefield in gastric cancer and role of immunotherapies. World J Gastroenterol 2016 0.76
37 PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report. J Immunother Cancer 2016 0.75
38 Prime time for immune-checkpoint targeted therapy at ASCO 2015. Oncoimmunology 2015 0.75
39 State of the art management of metastatic gastroesophageal cancer. Ann Transl Med 2015 0.75
40 Novel immunotherapeutic approaches to the treatment of urothelial carcinoma. Ther Adv Urol 2016 0.75
Next 100